Physician profile
Olivia Lin Alpert
NPI 1447733894
$3,647.74
in general payments reported to CMS, 2019-2025
21 companies · $2,291 in 2025
The $2,291 reported for 2025 was more than what 93% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $34.41 · 2022: $209 · 2023: $64.02 · 2024: $1,050 · 2025: $2,291.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,253 · Education: $152.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,252.56 |
| Education | $151.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $527.20 | 2024-2025 | |
| Incyte Corporation | $410.66 | 2022-2025 | Opzelura |
| Janssen Biotech, INC. | $328.34 | 2024-2025 | Tremfya |
| Amgen INC. | $310.89 | 2024-2025 | Otezla, Otezla |
| Galderma Laboratories, L.P. | $290.42 | 2024-2025 | Nemluvio, Aklief |
| E.R. Squibb & Sons, L.L.C. | $287.43 | 2024-2025 | Sotyktu |
| Lilly USA, LLC | $250.72 | 2024-2025 | Ebglyss, Taltz, Olumiant |
| Ucb, INC. | $201.58 | 2025 | Bimzelx |
| Novartis Pharmaceuticals Corporation | $159.07 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $136.59 | 2024-2025 | Dupixent |
| Pfizer INC. | $136.42 | 2022-2025 | |
| Leo Pharma INC. | $130.39 | 2022-2025 | Anzupgo, Adbry |
| Sun Pharmaceutical Industries INC. | $109.32 | 2021-2025 | |
| Genzyme Corporation | $92.08 | 2024-2025 | |
| Arcutis Biotherapeutics, INC. | $92.05 | 2024-2025 | Zoryve |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $79.99 | 2025 | |
| Organon LLC | $30.56 | 2025 | Vtama |
| Strata Skin Sciences, INC. | $26.20 | 2025 | Xtrac |
| Tempus Ai, INC | $23.00 | 2024 | |
| Dermavant Sciences, INC. | $14.34 | 2024 | Vtama |
| Biofrontera INC. | $10.49 | 2024 | Ameluz, Rhodoled Xl, Xepi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Olivia Alpert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.